Serum melatonin is inversely associated with matrix metalloproteinase‑9 in oral squamous cell carcinoma

Stanciu,Adina  Elena; Zamfir‑Chiru‑Anton,Adina; Stanciu,Marcel  Marian; Pantea‑Stoian,Anca; Nitipir,Cornelia; Gheorghe,Dan  Cristian

doi:10.3892/ol.2020.11392

Serum melatonin is inversely associated with matrix metalloproteinase‑9 in oral squamous cell carcinoma

Authors:
- Adina Elena Stanciu
- Adina Zamfir‑Chiru‑Anton
- Marcel Marian Stanciu
- Anca Pantea‑Stoian
- Cornelia Nitipir
- Dan Cristian Gheorghe
View Affiliations

Affiliations: Department of Carcinogenesis and Molecular Biology, Institute of Oncology Bucharest, Bucharest 022328, Romania, ENT Department, Grigore Alexandrescu Children's Emergency Hospital and Coltea Clinical Hospital, Bucharest 011743, Romania, Electrical Engineering Faculty, Politehnica University of Bucharest, Bucharest 060042, Romania, Department of Hygiene, Carol Davila University of Medicine and Pharmacy, Bucharest 050474, Romania, Department of Medical Oncology, Elias University Emergency Hospital, Bucharest 011461, Romania, ENT Department, Maria Sklodowska Curie Children's Emergency Hospital, Bucharest 077120, Romania
Published online on: February 13, 2020 https://doi.org/10.3892/ol.2020.11392
Pages: 3011-3020

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix‑metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) expression levels have been demonstrated to have prognostic value in oral squamous cell carcinoma (OSCC). The present study hypothesized that melatonin, a small lipophilic molecule primarily secreted by the pineal gland, may be able to regulate MMP activity in OSCC progression. This study aimed to investigate the associations between melatonin, MMPs, TIMPs and the histopathological characteristics of patients with OSCC. A total of 40 men with OSCC (mean age, 57±7 years) and 30 healthy men (mean age, 56±5 years) were enrolled in the present study. Enzyme immunoassays were used to measure the serum levels of melatonin, MMP‑9, MMP‑2, TIMP‑1 and TIMP‑2 before and after transoral surgery for OSCC. Serum melatonin level was significantly lower in patients with OSCC compared with controls, both pre‑surgery and 2 days after surgery (P<0.001). In addition, melatonin level was negatively correlated with MMP‑9 (r=‑0.6371) and the MMP‑9/TIMP‑1 ratio (r=‑0.4700), but not with the MMP‑2 or MMP‑2/TIMP‑2 ratio, in patients with OSCC. These results demonstrated that low levels of melatonin and high levels of MMP‑9 correlated with large tumors with invasive depth (r=‑0.35 and r=0.33) and lymph node metastasis (r=‑0.56 and r=0.34). The results of this retrospective clinical study suggested that melatonin may be considered as a predictive biomarker of tumor growth and metastasis and a potential therapeutic agent for patients with OSCC.

View Figures

View References

1	Yeh CM, Su SC, Lin CW, Yang WE, Chien MH, Reiter RJ and Yang SF: Melatonin as a potential inhibitory agent in head and neck cancer. Oncotarget. 8:90545–90556. 2017. View Article : Google Scholar : PubMed/NCBI
2	Stanciu AE, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC and Nitipir C: Serum matrix metalloproteinase-2 in head and neck squamous cell carcinoma is associated with tumor differentiation. Rom Biotech Lett. 22:12419–12426. 2017.
3	Koziorowski J, Stanciu AE, Gomez-Vallejo V and Llop J: Radiolabeled nanoparticles for cancer diagnosis and therapy. Anticancer Agents Med Chem. 17:333–354. 2017. View Article : Google Scholar : PubMed/NCBI
4	Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
5	Stanciu AE, Vatasescu RG, Stanciu MM, Serdarevic N and Dorobantu M: The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine. 103:63–68. 2018. View Article : Google Scholar : PubMed/NCBI
6	Stanciu AE, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR and Gheorghe DC: Imbalance between matrix metalloproteinases and tissue inhibitors of metalloproteinases promotes invasion and metastasis of head and neck squamous cell carcinoma. Clin Lab. 63:1613–1620. 2017. View Article : Google Scholar : PubMed/NCBI
7	Patel BP, Shah SV, Shukla SN, Shah PM and Patel PS: Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 29:564–572. 2007. View Article : Google Scholar : PubMed/NCBI
8	Stanciu AE, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR and Gheorghe DC: Serum level of matrix metalloproteinase-9 in patients with head and neck squamous cell carcinoma. Clin Lab. 62:1569–1574. 2016. View Article : Google Scholar : PubMed/NCBI
9	Burduk PK, Sawicki P, Szylberg L, Bodnar M and Marszalek A: Expression of matrix metalloproteinase-2/9 and tissue inhibitor of metalloproteinase-1/2 as predictive factors in oropharyngeal squamous cell carcinoma. Iran J Otorhinolaryngol. 31:153–161. 2019.PubMed/NCBI
10	Hanedan Uslu G, Canyilmaz E, Serdar L and Ersöz S: Protective effects of genistein and melatonin on mouse liver injury induced by whole-body ionising radiation. Mol Clin Oncol. 10:261–266. 2019.PubMed/NCBI
11	Laurent V, Sengupta A, Sánchez-Bretaño A, Hicks D and Tosini G: Melatonin signaling affects the timing in the daily rhythm of phagocytic activity by the retinal pigment epithelium. Exp Eye Res. 165:90–95. 2017. View Article : Google Scholar : PubMed/NCBI
12	Siah KT, Wong RK and Ho KY: Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol. 20:2492–2498. 2014. View Article : Google Scholar : PubMed/NCBI
13	Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, Slominski RM and Tobin DJ: On the role of melatonin in skin physiology and pathology. Endocrine. 27:137–148. 2005. View Article : Google Scholar : PubMed/NCBI
14	Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M and Maestroni JM: Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res. 28:193–202. 2000. View Article : Google Scholar : PubMed/NCBI
15	Isola M and Lilliu MA: Melatonin localization in human salivary glands. J Oral Pathol Med. 45:510–515. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yang WS, Deng Q, Fan WY, Wang WY and Wang X: Light exposure at night, sleep duration, melatonin, and breast cancer: A dose-response analysis of observational studies. Eur J Cancer Prev. 23:269–276. 2014. View Article : Google Scholar : PubMed/NCBI
17	Tai SY, Huang SP, Bao BY and Wu MT: Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case control study. Sci Rep. 6:296062016. View Article : Google Scholar : PubMed/NCBI
18	Zhao M, Wan JY, Zeng K, Tong M, Lee AC, Ding JX and Chen Q: The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: A retrospective study. J Cancer. 7:831–836. 2016. View Article : Google Scholar : PubMed/NCBI
19	Chok KC, Ng CH, Koh RY, Ng KY and Chye SM: The potential therapeutic actions of melatonin in colorectal cancer. Horm Mol Biol Clin Investig. May 29–2019.(Epub ahead of print). doi: 10.1515/hmbci-2019-0001. View Article : Google Scholar : PubMed/NCBI
20	Lu H, Wu B, Ma G, Zheng D, Song R, Huang E, Mao M and Lu B: Melatonin represses oral squamous cell carcinoma metastasis by inhibiting tumor-associated neutrophils. Am J Transl Res. 9:5361–5374. 2017.PubMed/NCBI
21	Yeh CM, Lin CW, Yang JS, Yang WE, Su SC and Yang SF: Melatonin inhibits TPA-induced oral cancer cell migration by suppressing matrix metalloproteinase-9 activation through the histone acetylation. Oncotarget. 7:21952–21967. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ho HY, Lin CW, Chien MH, Reiter RJ, Su SC, Hsieh YH and Yang SF: Melatonin suppresses TPA-induced metastasis by downregulating matrix metalloproteinase-9 expression through JNK/SP-1 signaling in nasopharyngeal carcinoma. J Pineal Res. 61:479–492. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yang CY, Lin CK, Tsao CH, Hsieh CC, Lin GJ, Ma KH, Shieh YS, Sytwu HK and Chen YW: Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models. Oncotarget. 8:33756–33769. 2017.PubMed/NCBI
24	Mannello F, Jung K, Tonti GA and Canestrari F: Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem. 41:1466–1473. 2008. View Article : Google Scholar : PubMed/NCBI
25	Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual, eighth edition (2017) published by Springer Science and Business Media LLC (springer.com). AJCC Cancer Staging Manual. 8th. Springer; New York, NY: 2017, View Article : Google Scholar
26	Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM and Shah JP: Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:122–137. 2017. View Article : Google Scholar : PubMed/NCBI
27	El-Naggar AK, Chan JKC, Grandis JR, Takata T and Slootweg PJ: WHO Classification of Head and Neck Tumours. WHO Classification of Tumours. 4th. 9. WHO Press; Geneva: 2017
28	Kennaway DJ: A critical review of melatonin assays: Past and present. J Pineal Res. 67:e125722019. View Article : Google Scholar : PubMed/NCBI
29	Karkela J, Vakkuri O, Kaukinen S, Huang WQ and Pasanen M: The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiol Scand. 46:30–36. 2002. View Article : Google Scholar : PubMed/NCBI
30	Vacas S, Kurien P and Maze M: Sleep and Anesthesia Common mechanisms of action. Sleep Med Clin. 8:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
31	Norouzi A, Fateh S, Modir H, Kamali A and Akrami L: Premedication effect of melatonin on propofol induction dose for anesthesia, anxiety, orientation and sedation after abdominal surgery: A double-blinded randomized trial. Med Gas Res. 9:62–67. 2019.PubMed/NCBI
32	Wang G, Liu J, Gao J and Zheng X: Comparison of the effects of sevoflurane and propofol anesthesia on pulmonary function, MMP-9 and postoperative cognition in patients receiving lung cancer resection. Oncol Lett. 17:3399–3405. 2019.PubMed/NCBI
33	Vasaturo F, Solai F, Malacrino C, Nardo T, Vincenzi B, Modesti M and Scarpa S: Plasma levels of matrix metalloproteinases 2 and 9 correlate with histological grade in breast cancer patients. Oncol Lett. 5:316–320. 2013. View Article : Google Scholar : PubMed/NCBI
34	Lin FY, Lin CW, Yang SF, Lee WJ, Lin YW, Lee LM, Chang JL, Weng WC, Lin CH and Chien MH: Interactions between environmental factors and melatonin receptor type 1A polymorphism in relation to oral cancer susceptibility and clinicopathologic development. PLoS One. 10:e01216772015. View Article : Google Scholar : PubMed/NCBI
35	Lin FY, Hsieh YH, Yang SF, Chen CT, Tang CH, Chou MY, Chuang YT, Lin CW and Chen MK: Resveratrol suppresses TPA-induced matrix metalloproteinase-9 expression through the inhibition of MAPK pathways in oral cancer cells. J Oral Pathol Med. 44:699–706. 2015. View Article : Google Scholar : PubMed/NCBI
36	Lin YW, Lee LM, Lee WJ, Chu CY, Tan P, Yang YC, Chen WY, Yang SF, Hsiao M and Chien MH: Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity. J Pineal Res. 60:277–290. 2016. View Article : Google Scholar : PubMed/NCBI
37	Rudra DS, Pal U, Maiti NC, Reiter RJ and Swarnakar S: Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site. J Pineal Res. 54:398–405. 2013. View Article : Google Scholar : PubMed/NCBI
38	Stanciu AE, Zamfir-Chiru-Anton A, Stanciu MM, Pantea Stoian A, Jinga V, Nitipir C, Bucur A, Pituru TS, Arsene AL, Dragoi CM, et al: Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. Oncol Lett. 19:1537–1543. 2019.PubMed/NCBI
39	Nakamura E, Kozaki K, Tsuda H, Suzuki E, Pimkhaokham A, Yamamoto G, Irie T, Tachikawa T, Amagasa T, Inazawa J and Imoto I: Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci. 99:1390–400. 2008. View Article : Google Scholar : PubMed/NCBI